13F filing recap · Q2 2010

What did ValueAct Capital buy in Q2 2010?

Reported stock-position changes between this filing and the previous one.

Stock value

$3.06B

Positions

Estimated turnover

35.9%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

WTWWillis Towers Watson Plc$231.91Mreported value+7.72M shares NTYNbty Inc$49.81Mreported value+1.46M shares

Increased positions

VRSNVeriSign Inc/ca$302.99Mreported value+4.16M shares+57.4%BCRC.r. Bard, Inc.$228.14Mreported value+241.9K shares+9.0%SNASnap-On Inc$149.47Mreported value+1.90M shares+108.9%IU1Immucor Inc$143.65Mreported value+2.66M shares

Reduced positions

VRXValeant Pharmaceuticals International, Inc.$791.59Mreported value-2.64M shares-14.8%

Exited positions

WSHWillis Group Holdings Plc$187.44Mprior reported value-5.99M shares-100.0%MDZMds Inc$78.94Mprior reported value-9.73M shares-100.0%BFHBread Financial Holdings, Inc.$32.00Mprior reported value-500.0K shares-100.0%MYGNMyriad Genetics, Inc.$14.96Mprior reported value-622.0K shares